Spectrum volatility flat into disappointing Fusilev sales forecasts Spectrum overall option implied volatility of 54 is near its 26-week average of 55 according to Track Data, suggesting non-directional price movement into the company's disappointing Fusilev sales forecasts.
News For SPPI From The Last 14 Days
Check below for free stories on SPPI the last two weeks.
Spectrum reports Q1 EPS (5c), consensus (16c) Reports Q1 revenue $38.7M, consensus $36.42M. Says pivotal data in relapsed/refractory peripheral T-cell lymphoma from late-stage drug Belinostat to be presented as an oral presentation at ASCO 2013; the company expects to submit an NDA this summer. Company expects enrollment in the Captisol-enabled melphalan study in multiple myeloma to be completed in 2013, with NDA submission in 2014.
Subscribe for More Information